Oxymetazoline
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
Oxymetazoline: From Pharyngitis and Common Cold to Nasal Cavity Disease
One-Sentence Summary
Oxymetazoline is a topical alpha-adrenergic decongestant, originally used for pharyngitis and the common cold. The TxGNN model predicts it may be effective for nasal cavity disease, but there are currently no registered clinical trials and only 5 publications (mostly animal, case-report or indirect studies) supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Pharyngitis, common cold |
| Predicted New Indication | Nasal cavity disease |
| TxGNN Prediction Score | 99.96% |
| Evidence Level | L3 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 10 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Pharmacology data show that oxymetazoline binds alpha-1 (A, B, D) and alpha-2 (A, B, C) adrenoceptors, as well as the serotonin receptors 5-HT1B, 5-HT1D and 5-HT2C. It is a sympathomimetic used to relieve nasal congestion and eye irritation. An ophthalmic solution (Upneeq®) was approved by the FDA in July 2020 for acquired blepharoptosis.
Stimulating alpha-adrenergic receptors constricts blood vessels in the nasal mucosa, reducing swelling, blood flow and congestion. This is plausible for nasal cavity conditions involving mucosal swelling or bleeding. However, the existing use for nasal congestion already largely overlaps with this predicted indication, so it is closer to an extension of the current label than a true repurposing opportunity.
Other predicted indications are weaker. Acute laryngopharyngitis and nasopharyngitis are closely related to the original indications but have no supporting studies. A headache disorder prediction has some support (intranasal tetracaine plus oxymetazoline for status migrainosus), but this is a combination product, so oxymetazoline's own contribution cannot be separated. Several other predictions (e.g., cervical disc degenerative disorder, allergic urticaria, faucial diphtheria, massive neonatal aspiration syndrome) have no plausible mechanistic link and are likely spurious.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 9929658 | 1998 | Clinical study | Ann N Y Acad Sci | Effects of acute rhinitis (common cold) on olfactory function in 36 subjects, using evoked potentials and acoustic rhinometry of nasal volume |
| 8615587 | 1996 | Animal study | Ann Otol Rhinol Laryngol | Oxymetazoline nose drops in rabbit acute sinusitis; evaluated effect on early local tissue defense in experimental bacterial infection |
| 25496205 | 2015 | Clinical study | J Plast Surg Hand Surg | Nasal patency measured by acoustic rhinometry in children after cleft lip and palate repair (indirect relevance) |
| 28490409 | 2017 | Case series / procedural | Am J Rhinol Allergy | Coblation treatment of nasal telangiectasias in hereditary hemorrhagic telangiectasia (indirect relevance) |
| 38024464 | 2023 | Case report | Glob Pediatr Health | Rhinoscleroma in a 9-year-old boy (indirect relevance) |
None of these studies is a randomized trial of oxymetazoline for nasal cavity disease. The only directly relevant study of the drug is the animal study.
Singapore Market Information
Ten valid single-ingredient licences are registered. The approved indication text is not available for any of them. The five main ones are:
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN02674P | ILIADIN SPRAY 0.05% | Spray | Not specified |
| SIN10520P | NAZOLIN NASAL SPRAY 0.05% | Spray | Not specified |
| SIN02656P | CLARICLEAR NASAL SPRAY 0.05% | Spray | Not specified |
| SIN03162P | ILIADIN SOLUTION 0.025% | Solution | Not specified |
| SIN09618P | OXY-NASE NASAL DROPS 0.025% | Solution | Not specified |
Safety Considerations
Package insert warnings and contraindications were not available. Please refer to the package insert for safety information.
The following comes from knowledge-graph contraindication links (not label text) and should be verified against the label. Oxymetazoline is linked as contraindicated or to be used with caution in:
- Cardiovascular: hypertension, heart disease, cardiovascular disease, coronary artery disease, arteriosclerosis, atherosclerosis
- Metabolic and endocrine: diabetes mellitus, diabetic ketoacidosis, hyperthyroidism, Graves disease, thyrotoxicosis
- Eye: angle-closure glaucoma, eye infectious disease, conjunctivitis, vision disorder, blindness
- Urological: benign prostatic hyperplasia
Drug interactions: The interaction query found no drug–drug interactions. The 9 entries returned are receptor binding records (5-HT1B, 5-HT1D, 5-HT2C, alpha-1A/1B/1D, alpha-2A/2B/2C), not clinical interactions. The alpha-adrenergic and serotonergic activity suggests possible cardiovascular effects, so caution is warranted with other sympathomimetics, MAO inhibitors and antihypertensives, but this is not confirmed by the data.
Conclusion and Next Steps
Decision: Hold
Rationale: Oxymetazoline is already marketed in Singapore as a nasal decongestant, so "nasal cavity disease" largely overlaps with its existing use rather than representing a new indication. Supporting evidence is limited to an animal study and indirect clinical or case literature, with no registered trials. The other nine predictions are mostly unsupported, and the headache signal comes from a combination product. In addition, the package insert safety data are missing.
To proceed, the following is needed:
- Singapore package insert warnings, contraindications and approved indication text for the 10 licences
- Detailed mechanism of action data from DrugBank
- Clarification of which specific nasal cavity conditions go beyond the current label
- Controlled clinical evidence, such as RCTs, for any non-label indication (e.g., oxymetazoline alone in headache or migraine)
- A safety review given the cardiovascular, endocrine and eye-related contraindication signals
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.